Case Study

GlaxoSmithKline and AIDS drugs in South Africa (A): The fight for lives and profits

10 pages
February 2005
Reference: IMD-3-1496

The case describes the interactions among pharmaceutical companies, NGOs, and governments in the context of the AIDS epidemic in South Africa. Oxfam singled out GSK as the target for its new campaign, “Cut the Cost.” The goal was to hit where it would hurt the most–GSK’s share price. At the same time other NGOs also went after GSK. For GSK the situation in South Africa was extremely delicate. The ultimate issues were patent and price protection globally. The pharmaceutical companies were afraid that cheap generic drugs could flood the West, undermining the entire pricing structure and their ability to fund new research. Defending the patents and prices seemed essential. Yet, fighting the NGOs could bring negative publicity and, ultimately, be self-defeating. Meanwhile, million of people were dying of AIDS in South Africa.

Keywords
Non-market Competition, Ethics, Pharmaceuticals, AIDS
Settings
Africa, South Africa
GlaxoSmithKline, Healthcare, Pharmaceuticals
2001-2004
Type
Published Sources
Copyright
© 2005
Available Languages
English
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

This case study is part of a series
  • GlaxoSmithKline and AIDS drugs in South Africa (A): The fight for lives and profits
  • GlaxoSmithKline and AIDS drugs in South Africa (B): The settlement
  • GlaxoSmithKline and AIDS drugs in South Africa (C): The fight goes on
  • GlaxoSmithKline and AIDS drugs in South Africa (D): US developments
This case study is part of a series
  • GlaxoSmithKline and AIDS drugs in South Africa (A): The fight for lives and profits
  • GlaxoSmithKline and AIDS drugs in South Africa (B): The settlement
  • GlaxoSmithKline and AIDS drugs in South Africa (C): The fight goes on
  • GlaxoSmithKline and AIDS drugs in South Africa (D): US developments
Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics
GlaxoSmithKline and AIDS drugs in South Africa (A): The fight for lives and profits
By Michael Yaziji and Anna Lindblom
Case reference: IMD-3-1496 ©2005
Summary
The case describes the interactions among pharmaceutical companies, NGOs, and governments in the context of the AIDS epidemic in South Africa. Oxfa...
Reference IMD-3-1496
Copyright ©2005
Copyright owner IMD Copyright
Organization GlaxoSmithKline
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

GlaxoSmithKline and AIDS drugs in South Africa (B): The settlement
By Michael Yaziji and Anna Lindblom
Case reference: IMD-3-1497 ©2005
Summary
The B- part of the cases focuses on the outcome of the lawsuit against the South African government. But the demands from the NGOs keep on coming a...
Reference IMD-3-1497
Copyright ©2005
Copyright owner IMD Copyright
Organization GlaxoSmithKline
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

GlaxoSmithKline and AIDS drugs in South Africa (C): The fight goes on
By Michael Yaziji and Anna Lindblom
Case reference: IMD-3-1498 ©2005
Summary
The C- part of the cases focuses on the actions GSK had to take being pressured by the NGOs. The company had been defeated and it agreed to several...
Reference IMD-3-1498
Copyright ©2005
Copyright owner IMD Copyright
Organization GlaxoSmithKline
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

GlaxoSmithKline and AIDS drugs in South Africa (D): US developments
By Michael Yaziji and Anna Lindblom
Case reference: IMD-3-1499 ©2005
Summary
The D- case focuses on the developments in the US markets. The AIDS drugs issue that had begun in South Africa was beginning to feed a "perfect sto...
Reference IMD-3-1499
Copyright ©2005
Copyright owner IMD Copyright
Organization GlaxoSmithKline
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications